Comparison of extrinsic immunity in ALK-mutant and ALK-non-mutant tumors. (IMAGE)
Caption
A) The immune cell infiltration was revealed by leukocyte fraction, lymphocyte fraction, and tumor-infiltrating lymphocyte fraction in ALK-mutant and ALK-non-mutant tumors. (B) The abundances of neoantigens and the diversity of TCR/BCR in ALK-mutant and ALK-non-mutant tumors. (C) mRNA expression levels of three major immune checkpoints, namely PD-1, PD-L1, and CTLA-4, in patients with ALK-mutant and ALK-non-mutant tumors. (D) Differences of 29 immune signatures estimated by ssGSEA between ALK-mutant and ALK-non-mutant tumors. (E) Comparison of 30 chemokines and 18 chemokine receptors between ALK-mutant and ALK-non-mutant tumors. (F) Expression differences of 39 immune-stimulators between ALK-mutant and ALK-non-mutant tumors. ALK, anaplastic lymphoma kinase; BCR, B cell receptor; SNV, single-nucleotide variant; TCR, T cell receptor; TIL, tumor-infiltrating lymphocyte; PD-L1, programmed cell death ligand 1; PD-1, programmed cell death protein 1; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4.
Credit
Zhiyang Huang, Jiajun Chen, Yan Huang, Hong Zhao, Bin Zhao
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND